http://www.fresenius.com en-us Thu, 06 May 2021 00:00:00 +0200 Thu, 06 May 2021 00:00:00 +0200 Thu, 06 May 2021 08:00:00 +0100 <![CDATA[Fresenius with good start to 2021 despite ongoing COVID-19 impact]]> Guidance for 2021 confirmed - Fresenius Medical Care delivers solid first quarter - Fresenius Kabi shows strong performance in Emerging Markets whilst headwinds continue to impact North American business - Helios Germany continues to be compensated by government for foregone elective treatments; Helios Spain delivers significant sales and earnings growth given recovery of treatment activity - Fresenius Vamed continues to suffer from COVID-19 related project delays; technical high-end service business remains robust - Preparation of Group-wide initiatives to improve efficiency and profitability progressing

]]>
Tue, 23 Mar 2021 08:00:00 +0100 <![CDATA[Fresenius successfully places bonds with a volume of 1.5 billion euros]]> Fresenius successfully places bonds with a volume of 1.5 billion euros

]]>
Tue, 16 Mar 2021 08:00:00 +0100 <![CDATA[Michael Sen to succeed Mats Henriksson as CEO of Fresenius Kabi]]> Michael Sen (52) will become the new Chief Executive Officer of Fresenius Kabi AG. The Supervisory Board of Fresenius Management SE has unanimously appointed him to the Management Board of Fresenius effective on April 12, 2021.

]]>
Mon, 15 Mar 2021 08:00:00 +0100 <![CDATA[Fresenius Kabi launches IV Drug in the U.S.]]> Foscarnet Sodium Injection is now available in the United States, expanding the company’s anti-viral portfolio. The drug is used in the treatment of conditions associated with immunocompromised patients.

]]>
Tue, 23 Feb 2021 08:00:00 +0100 <![CDATA[Fresenius achieves 2020 targets and expects healthy business development in 2021 despite ongoing COVID-19 impact]]> Preliminary guidance for 2021 confirmed - Strategic roadmap for accelerated growth through 2023 and beyond - Group-wide initiatives to improve efficiency and profitability in preparation - Medium-term growth targets confirmed - 28th consecutive dividend increase proposed

]]>
Mon, 01 Feb 2021 08:00:00 +0100 <![CDATA[Fresenius achieves FY/20 guidance demonstrating resilience amid the COVID-19 pandemic – Targets healthy sales growth and at least broadly stable net income year over year in FY/21]]> Fresenius has proven the resilience of its business model in a challenging environment in FY/20. Based on preliminary and unaudited results, Fresenius achieved its sales and net income  guidance including COVID-19 effects.

]]>
Mon, 21 Dec 2020 08:00:00 +0100 <![CDATA[Fresenius Helios acquires fertility services provider Eugin Group]]> Fresenius Helios acquires Eugin Group, one of the leading international fertility groups. Eugin Group’s network comprises 31 clinics and additional 34 sites across 9 countries on 3 continents.

]]>
Fri, 11 Dec 2020 08:00:00 +0100 <![CDATA[Fresenius improves in climate ranking ]]> Fresenius has once again improved in this year's CDP ranking (formerly "Carbon Disclosure Project"). With a ranking in the second highest category B, Fresenius is one of the leading companies in the health care sector, both in Europe and globally. Companies in categories A and B are characterized by transparency, coordinated climate protection measures and the implementation of corresponding best-practice approaches. CDP is one of the most renowned climate and environmental rankings in the capital market. More than 515 investors use the annual results to evaluate climate protection activities and climate-related risks and opportunities of the companies assessed.

]]>
Thu, 10 Dec 2020 08:00:00 +0100 <![CDATA[Fresenius Kabi launches IV Drug in the U.S.]]> Acetaminophen injection is now available in the United States in ready-to-administer freeflex® bags, expanding the company’s anesthesia and analgesia portfolio. The drug is used in the hospital setting for pain management and fever reduction.

]]>
Tue, 01 Dec 2020 08:00:00 +0100 <![CDATA[Fresenius Kabi launches its first specialty IV drug in the U.S.]]> Icatibant injection, an FDA-approved and cost-effective alternative to treat acute attacks of hereditary angioedema in adults, expands the company’s generic drug portfolio. Icatibant Injection is supplied as a prefilled, single-use syringe that is self-administered subcutaneously at the patient’s home or doctor’s office. In conjunction with launching its first specialty IV drug in the U.S., Fresenius Kabi is also launching KabiCare in the U.S., a comprehensive patient support program with case managers, co-pay assistance programs, injection training, and a patient assistance program.

]]>
Mon, 02 Nov 2020 08:00:00 +0100 <![CDATA[Fresenius Helios reporting figures on intensive care occupancy]]> Fresenius Helios has started publishing daily figures on the occupancy rate for intensive care beds in its 86 German hospitals. The website of each hospital will report the number of COVID-19 patients in the hospital’s regular and intensive care wards. It will also publish figures from the Robert Koch Institute, Germany’s national health agency, on the number of new infections in the surrounding region. Helios’ goal is to increase transparency and facilitate a data-based assessment of the pandemic at the local level. Helios Germany currently has a total of 1,300 intensive care beds across the country and could add an additional 1,000 on short notice, in the event of a sharp increase in COVID-19 hospitalizations.

]]>
Thu, 29 Oct 2020 08:00:00 +0100 <![CDATA[Fresenius continues to demonstrate resilience amid the COVID-19 pandemic: FY/20 guidance confirmed given accelerated earnings growth in Q3]]> Fresenius Medical Care with continued strong earnings growth in constant currency - Fresenius Kabi showed a recovery in Europe and return to growth in China whilst headwinds weigh on North American business - Helios Germany with sales growth in Q3 due to recovery of elective procedures; Helios Spain with significant growth based on catch-up effects - Fresenius Vamed continues to be heavily impacted by COVID-19 related project delays, high-end technical service remained robust

]]>
Tue, 13 Oct 2020 08:00:00 +0100 <![CDATA[Fresenius announces changes to Supervisory Board]]> Wolfgang Kirsch, 65, a Member of the Supervisory Board of Fresenius Management SE since the start of this year, is to become the board’s Chairman. This was decided unanimously today by the Supervisory Board of Fresenius Management SE. At the Annual General Meeting in May 2021 he will also stand for election to the Supervisory Board of the publicly listed Fresenius SE & Co. KGaA, with the goal of assuming its chairmanship, as well.

]]>
Fri, 09 Oct 2020 08:00:00 +0100 <![CDATA[Fresenius Helios expands reporting on quality standards]]> As part of its reporting on quality standards, Fresenius Helios is publishing data on the length of patient stays, patient security and antibiotic use in the company’s German hospitals for the first time. Data from every Helios hospital is compiled in a total of 46 quality categories, including the frequency of surgical interventions and their results, and then published annually. The comparing of different hospitals’ statistics through the Quality Medicine Initiative yields specific, concrete improvements that can be implemented in day-to-day hospital operations. The initiative, which was jointly founded by Fresenius Helios, now includes more than 400 hospitals in Germany and Switzerland.

]]>
Thu, 08 Oct 2020 08:00:00 +0100 <![CDATA[Fresenius Kabi launches its first RFID smart-labeled product in the U.S.]]> Diprivan® (Propofol) injection, an anesthetic, is the company’s first smart-labeled product with radio frequency identification (RFID) technology and the 20 mL vial is now available in this enhanced presentation in the U.S. The smart label enables hospitals to automatically identify, locate and manage their inventory. Fresenius Kabi expects to introduce numerous other products with RFID technology in the coming year.

]]>
Wed, 07 Oct 2020 08:00:00 +0100 <![CDATA[Fresenius Helios enters healthcare agreement with hotel operator in Spain]]> Quirónsalud, the Spanish hospital group that is part of Fresenius Helios, has signed an agreement with Vincci Hotels to offer health careto guests in all accommodations in Spain. The service includes 24/7 medical assistance, either by video call, in person or by a doctor’s visit in the hotel, if necessary. This service is offered in several languages to meet the demands from international guests.

]]>
Mon, 21 Sep 2020 08:00:00 +0100 <![CDATA[Fresenius successfully places bonds with a volume of one billion euros]]> Fresenius today successfully placed bonds with an aggregate volume of €1.0 billion.

]]>
Mon, 14 Sep 2020 08:00:00 +0100 <![CDATA[2021 DRG inflator for German hospitals set at 2.53% ]]> The price increase for hospital services in Germany has been set at 2.53% for 2021. As it is subject to negotiations at the state level as well as individual hospital discounts, the final price increase on the individual hospital level will, however, be lower.

]]>
Tue, 25 Aug 2020 08:00:00 +0100 <![CDATA[Fresenius Helios publishes study on intensive care COVID-19 patients]]> Fresenius Helios has published initial results from a study of all COVID-19 patients admitted to Helios hospitals in Germany that has been conducted since the start of the pandemic: Two of every three COVID-19 patents in intensive care in Germany require mechanical ventilation. One-third of ventilated intensive care patients die, compared with one-quarter of non-ventilated intensive care patients. This shows that the clinical course of COVID-19 patients in Germany is as poor as in countries hit harder by the pandemic such as Italy, France, the United Kingdom and Belgium. Helios, supported by the Brandenburg Medical School, started in February to collect and analyze data on COVID-19 patents treated in the Helios’ 86 German hospitals. These and additional findings that Helios makes from the study are expected to help in the development of a treatment for the virus.

]]>
Thu, 20 Aug 2020 08:00:00 +0100 <![CDATA[Fresenius acquires Malteser hospitals in German state of North Rhine-Westphalia]]> Fresenius Helios is acquiring three hospitals and four connected medical care centers in the western German cities of Duisburg and Krefeld from the Malteser humanitarian aid group. The facilities have a total of 870 beds, and sales last year were about €160 million.

]]>